0001493152-26-018562
SEC filingVivos Therapeutics received Nasdaq notice of noncompliance with $2.5M minimum stockholders' equity rule due to negative $1.55M equity as of Dec 31, 2025, with 45 days to submit compliance plan.
Vivos Therapeutics faces a critical Nasdaq listing compliance challenge after the Staff notified the company on April 17, 2026, of deficient stockholders' equity reported at negative $1.55 million in its 2025 Form 10-K, breaching the $2.5 million minimum under Rule 5550(b)(1). This deficiency stems from year-end financials and carries no immediate delisting effect but triggers a tight 45-day window ending June 1, 2026, to propose a remediation plan. Acceptance could yield up to 180 days through October 14, 2026, for cure via further financings or operational gains. The company has proactively raised $6.8 million in Q1 2026 equity transactions—a $4.6 million warrant inducement and $2.25 million private placement—signaling fundraising capability, though insufficient alone to resolve the issue. Failure at any stage risks a delisting determination, appealable via Nasdaq Hearings Panel with a stay, but success is uncertain. Delisting would materially harm liquidity, operations, reputation, and investor confidence, underscoring urgency for equity strengthening.